Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Looks To Combination Regimens To Maximize Oncology Pipeline Value

Executive Summary

Pfizer is seeking to maximize the value of its oncology pipeline by developing combination regimens, Senior VP-Worldwide Development Declan Doogan said Nov. 30

You may also be interested in...



Pfizer’s Axitinib May Have Survival Benefit Over Tarceva In Pancreatic Cancer

Pfizer's oral selective VEGF inhibitor axitinib in combination with standard chemotherapy improves overall survival by 1.3 months and decreased the risk of death by 33 percent compared to standard care in advanced pancreatic cancer patients, the firm reported during a June 4 presentation at the American Society of Clinical Oncology meeting in Chicago

Pfizer’s Axitinib May Have Survival Benefit Over Tarceva In Pancreatic Cancer

Pfizer's oral selective VEGF inhibitor axitinib in combination with standard chemotherapy improves overall survival by 1.3 months and decreased the risk of death by 33 percent compared to standard care in advanced pancreatic cancer patients, the firm reported during a June 4 presentation at the American Society of Clinical Oncology meeting in Chicago

Pfizer Better Able To De-Risk First-In-Class Compounds, R&D Head Says

Pfizer has become more effective at controlling the development risk of investigational compounds with novel mechanisms of action, Global Research & Development President John LaMattina asserted Nov. 30

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS047832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel